The development and use of the E75 (HER2 369-377) peptide vaccine

Future Oncol. 2016 Jun;12(11):1321-9. doi: 10.2217/fon-2015-0054. Epub 2016 Apr 5.


E75 (nelipepimut-S) is an immunogenic peptide derived from the HER2 protein. When combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), nelipepimut-S has been used as a vaccine that is capable of eliciting a robust anti-HER2 immune response. Early-phase clinical trials that enrolled women with node-positive or high-risk node-negative breast cancer who had been rendered disease free with standard of care therapy but were at risk for recurrence, demonstrated the vaccine to be safe with a suggestion of clinical benefit. Nelipepimut-S is currently being evaluated in a Phase III clinical trial. This article covers the preclinical and clinical development of nelipepimut-S.

Keywords: E75; breast cancer; cancer vaccine; nelipepimut-S; peptide.

MeSH terms

  • Animals
  • Breast Neoplasms / therapy*
  • Cancer Vaccines / pharmacology*
  • Clinical Trials as Topic
  • Drug Design
  • Female
  • Humans
  • Peptide Fragments / pharmacology*
  • Receptor, ErbB-2 / immunology*
  • Receptor, ErbB-2 / pharmacology
  • Vaccines, Subunit / pharmacology


  • Cancer Vaccines
  • HER2 peptide (369-377)
  • Peptide Fragments
  • Vaccines, Subunit
  • Receptor, ErbB-2